爾康製藥(300267.SZ):帥佳投資擬轉讓3.41%的股份予徐志琪
格隆匯7月2日丨爾康製藥(300267.SZ)公佈,公司收到持股5%以上股東湖南帥佳投資有限公司(“帥佳投資”)的通知,帥佳投資為歸還股票質押融資貸款、降低其股票質押比例,擬將其持有的公司無限售條件股份7033萬股(佔公司總股本比例為3.41%)以2.78元/股的價格轉讓給徐志琪,轉讓總價約1.96億元。
此次協議轉讓前,帥佳投資持有公司股份231,851,004股,佔公司總股本比例為11.24%;此次協議轉讓後,帥佳投資持有公司無限售流通股份161,521,004股,佔公司總股本比例為7.83%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.